MEDAREX
Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb® technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners.
MEDAREX
Industry:
Biotechnology Medical Device Therapeutics
Founded:
1987-01-01
Address:
Princeton, New Jersey, United States
Country:
United States
Website Url:
http://www.medarex.com
Total Employee:
10001+
Status:
Active
Contact:
+1 212-546-4000
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Apache Sitelinks Search Box Organization Schema COVID-19 PostalAddress Schema Amazon CloudFront ContactPoint Schema SEO_H2
Similar Organizations
Alethia BioTherapeutics
Alethia BioTherapeutics is a biotechnology company developing monoclonal antibody-based therapeutics for cancer-associated diseases.
PROLOR Biotech
PROLOR Biotech develops proprietary versions of already-approved therapeutic proteins.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Official Site Inspections
http://www.medarex.com
- Host name: 165.89.235.20
- IP address: 165.89.235.20
- Location: Trenton United States
- Latitude: 40.2187
- Longitude: -74.7404
- Metro Code: 504
- Timezone: America/New_York
- Postal: 08629
More informations about "Medarex"
Medarex - Wikipedia
Medarex was an American biopharmaceutical company based in Princeton, New Jersey, with manufacturing facilities in Bloomsbury and Annandale, New Jersey, and research facilities in Milpitas and Sunnyvale, California. In 2009, Medarex was purchased by Bristol Myers Squibb. Medarex developed … See moreSee details»
Medarex - Crunchbase Company Profile & Funding
Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, …See details»
Medarex - LinkedIn
Medarex is a biopharmaceutical company focused on the discovery, development, and potential commercialization of fully human antibody-based therapeutics to treat life- threatening and...See details»
Medarex Company Profile 2024: Valuation, Investors, Acquisition
Operator of a biopharmaceutical company intended to focus on developing human antibody-based therapeutics to treat life-threatening and debilitating diseases. The company specializes …See details»
Bristol-Myers Squibb to Acquire Medarex
Jul 22, 2009 · Bristol-Myers Squibb Company (NYSE:BMY) and Medarex, Inc. (NASDAQ:MEDX) announced today that the companies have signed a definitive merger agreement providing for …See details»
Bristol-Myers to buy Medarex for $2.4 billion | Reuters
Jul 23, 2009 · NEW YORK (Reuters) - U.S. drugmaker Bristol-Myers Squibb Co on Wednesday said it will pay $2.4 billion to acquire Medarex Inc , a biotechnology company that has been …See details»
Medarex, Inc. Company Profile | Princeton, NJ - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Medarex, Inc. of Princeton, NJ. Get the latest business insights from Dun & Bradstreet.See details»
Bristol-Myers Squibb to Acquire Medarex for $2.4 billion
Aug 4, 2009 · Medarex, which develops medicines to combat debilitating diseases, was trading at $8.40 a share when the market closed on July 22. Shortly thereafter BMS, the world’s 15th …See details»
Bristol-Myers Squibb swallows last of antibody pioneers
Medarex is one of the last independent public biotech companies that built their businesses around monoclonal antibodies (mAbs)—a business sector that now accounts for an estimated …See details»
Medarex - Funding, Financials, Valuation & Investors - Crunchbase
Sep 1, 2009 · Medarex, Inc. discovers, develops, and commercializes human antibody-based therapeutic products.See details»
Bristol/Medarex: A Transformational Acquisition Rooted In ... - In …
Sep 18, 2017 · From an early-stage platform technology collaboration to a multi-year co-development pact in cancer to an outright acquisition of the smaller company by the larger, …See details»
Medarex - Contacts, Employees, Board Members, Advisors & Alumni
Medarex, Inc. discovers, develops, and commercializes human antibody-based therapeutic products.See details»
Bristol-Myers Squibb to Acquire Medarex - Technology Networks
Jul 24, 2009 · Bristol-Myers Squibb acquires proven antibody discovery technology gains full rights to promising Phase III compound, Ipilimumab.See details»
Medarex, Inc. Announces Preclinical Data from Multiple ... - BioSpace
Apr 22, 2009 · Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life …See details»
The Celdara Team - Celdara Medical
With 40 FDA approvals for Medarex drugs and counting, and several hundred clinical trials completed and ongoing, this is only the tip of the iceberg. Indeed, Medarex’s platform has …See details»
About Us - Celldex Therapeutics
Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients.See details»
Medarex, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Medarex, Inc. with its drug pipeline, therapeutic area, technology platform, 18 clinical trials, 26 news, and 179 literature, Disease Domain:Neoplasms, Hemic and Lymphatic …See details»
Medarex | Insights
The Japanese academic discoverer of the PD-1 protein and the company that co-developed a blockbuster drug based on his work continue to be embroiled in a spat over patent royalties, …See details»
AbTherx Launches a Next-Generation Antibody Discovery Platform
Mountain View and San Diego, Calif. – June 7, 2023 – AbTherx, Inc., a privately held biotech company with novel technologies that accelerate antibody discovery, announced the launch of …See details»
Medarex, Inc. Release: Preliminary Data from Ongoing Phase 1
Jun 2, 2008 · Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world’s unmet healthcare needs. For more information about …See details»